Asthma–COPD overlap syndrome (ACOS) vs ‘pure’ COPD: a distinct phenotype?

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 72, Issue 1, 2017, Pages 137-145

  Caillaud, D ^a   Chanez, P ^b   Escamilla, R ^c   Burgel, P R ^d   Court Fortune, I ^e   Nesme Meyer, P ^f   Deslee, G ^g   Perez, T ^h   Paillasseur, J L ⁱ   Pinet, C ^j   Jebrak, G ^k   Roche, N ^d   Bourdin, A ^l   Brinchault Rabin, G ^l   Carre P ^l   Zysman, M ^l   Deslee G ^l  

^a SERVICE DE RHUMATOLOGIE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

^d Institut Cochin   (France)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g HÔPITAL MAISON BLANCHE   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ Effi Stat   (France)

^j Polyclinique les Fleurs   (France)

^k BICHAT HOSPITAL   (France)

^l NONE

more..

Author keywords

asthma COPD overlap syndrome; Asthma COPD overlap syndrome (ACOS); chronic obstructive pulmonary disease (COPD); mortality; severity; treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE; LONG ACTING DRUG; MUSCARINIC AGENT; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; ATOPIC DERMATITIS; ATOPY; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; DYSPNEA; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RESEARCH; MOOD DISORDER; MORTALITY; OBESITY; OCCUPATIONAL EXPOSURE; PHYSICIAN; POLLEN ALLERGY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESIDUAL VOLUME; RISK FACTOR; SMOKING; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TOTAL LUNG CAPACITY; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FRANCE; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; QUESTIONNAIRE; SYMPTOM ASSESSMENT; SYNDROME;

AGED; ASTHMA; COHORT STUDIES; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; SYMPTOM ASSESSMENT; SYNDROME;

EID: 84994711609     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13004     Document Type: Article

References (50)

1. GINA-GOLD. Asthma, COPD and asthma-COPD Overlap Syndrome. Global Initiative for Chronic Obstructive Lung Disease [Internet]. [Cited 2015 September 10]. Available from: htpp://www.goldcopd.org/asthma-copd-overlap.html. 2015.
2. Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis 2014;6(Suppl 1):S146–S151.
3. Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med 2015;373:1241–1249.
4. Soler-Cataluna JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Aguero R et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331–337.
5. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012;7:283–289.
6. Menezes AM, Montes de Oca M, Perez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 2014;145:297–304.
7. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011;12:127.
8. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014;44:341–350.
9. Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015;21:74–79.
10. Miravitlles M, Soriano JB, Ancochea J, Munoz L, Duran-Tauleria E, Sanchez G et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 2013;107:1053–1060.
11. Barnes PJ. Asthma-COPD overlap. Chest 2016;149:7–8.
12. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435–442.
13. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J 2007;14(Suppl B):5B–32B.
14. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014;50(Suppl 1):1–16.
15. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531–539.
16. de Marco R, Accordini S, Cerveri I, Corsico A, Anto JM, Kunzli N et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32–39.
17. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581–586.
18. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224–1238.
19. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007;167:60–67.
20. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1–252.
21. Burgel PR, Roche N, Paillasseur JL, Tillie-Leblond I, Chanez P, Escamilla R et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012;40:495–496.
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.
23. Talamo C, de Oca MM, Halbert R, Perez-Padilla R, Jardim JR, Muino A et al. Diagnostic labeling of COPD in five Latin American cities. Chest 2007;131:60–67.
24. Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, Unzueta I, Ribera X, Anton E et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013;107:724–731.
25. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008;14:176–185.
26. Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD 2011;8:400–407.
27. Meyer PA, Mannino DM, Redd SC, Olson DR. Characteristics of adults dying with COPD. Chest 2002;122:2003–2008.
28. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819–825.
29. Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007;4:127–134.
30. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007;132:1748–1755.
31. Fu JJ, Gibson PG, Simpson JL, McDonald VM. Longitudinal changes in clinical outcomes in older patients with asthma. COPD and asthma-COPD overlap syndrome. Respiration 2014;87:63–74.
32. Lange P, Colak Y, Ingebrigtsen TS, Vestbo J, Marott JL. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med 2016;4:454–462.
33. Cosio BG, Soriano JB, Lopez-Campos JL, Calle-Rubio M, Soler-Cataluna JJ, de Torres JP et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 2016; 149: 45–52.
34. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Eng J Med 1987;317:1309–1314.
35. O'Connell EJ. The burden of atopy and asthma in children. Allergy 2004;59(Suppl 78):7–11.
36. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813–824.
37. Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:187–192.
38. Busse PJ, Cohn RD, Salo PM, Zeldin DC. Characteristics of allergic sensitization among asthmatic 4 adults older than 55 years: results from the National Health and Nutrition Examination Survey, 2005-2006. Ann Allergy Asthma Immunol 2013;110:247–252.
39. Fingleton J, Travers J, Williams M, Charles T, Bowles D, Strik R et al, New Zealand Respiratory Health Survey Study Group. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol 2015;136:601–609.
40. Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, Roujeau JC, Revuz J, Societe Francaise de Parasitologie. French people and skin diseases: results of a survey using a representative sample. Arch Dermatol 2003;139:1614–1619.
41. Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17–27.
42. Frey U, Latzin P, Usemann J, Maccora J, Zumsteg U, Kriemler S. Asthma and obesity in children: current evidence and potential systems biology approaches. Allergy 2015;70:26–40.
43. Dixon AE, Holguin F, Sood A, Salome CM, Pratley RE, Beuther DA et al, American Thoracic Society Ad Hoc Subcommittee on Obesity and Lung Disease. An official American Thoracic Society Workshop report: obesity and asthma. Proc Am Thorac Soc 2010;7:325–335.
44. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661–666.
45. Sutherland TJ, Cowan JO, Young S, Goulding A, Grant AM, Williamson A et al. The association between obesity and asthma: interactions between systemic and airway inflammation. Am J Respir Crit Care Med 2008;178:469–475.
46. Fattahi F, ten Hacken NH, Lofdahl CG, Hylkema MN, Timens W, Postma DS et al. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res 2013;14:10.
47. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014;312:1114–1121.
48. Lim HS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol 2014;113:652–657.
49. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 2016;71:118–125.
50. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013;6:197–219.